Cybin, a biopharmaceutical firm focusing on advancing “Psychedelics to TherapeuticsTM,” has announced that its corporate-sponsored feasibility study, Kernel Flow, is currently seeking volunteers. The research involves analyzing the participants’ experiences wearing Kernel Flow while in an altered state of consciousness as a result of ketamine medication.
Participants will be given either a low dose of ketamine or a placebo while wearing the Kernel Flow headset, which is equipped with high-tech sensors to record brain activity, and will be asked to report their experiences using structured questionnaires and validated assessments during study visits and a follow-up. The trial will also assess brain activity before and after delivery of the study medications, either low-dosed ketamine or a placebo.
“The feasibility study employing Kernel Flow provides a chance for academics and our study participants to quantifiably acquire information on a psychedelic experience,” stated Cybin CEO Doug Drysdale. “Until recently, our knowledge of the psychedelic experience has been rather subjective.” This research might pave the way for bigger studies that could bridge the gap between bringing psychedelics to treatments as we understand more about the benefits of these essential chemicals on brain activity and general mental well-being.”
Concerning Kernel Flow
Kernel Flow is a wearable headgear that records local changes in blood oxygenation to evaluate brain function. It is adaptable, can fit almost everyone, and is safe. Kernel Flow is a game-changing neurotechnology that lowers noisy, costly, and room-sized equipment to a head-worn gear while producing the finest optical quality cerebral activity data. This combination has never existed in such a commercial and scalable device, which is why brain interfaces and neuroimaging technologies have mostly stayed in academic laboratories or hospital basements, and why behavioral, rather than biomarker, endpoints are used in mental health diagnosis and treatment. The complete apparatus is the size and shape of a bicycle helmet and might be utilized for neuroscientific or physiological research of brain activity during psychedelic usage in the future.
Concerning Cybin
Cybin is a leading ethical biopharmaceutical firm that collaborates with a network of world-class partners and globally known scientists to develop safe and effective treatments for patients suffering from a variety of mental health conditions. Cybin, headquartered in Canada and formed in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The Company is committed to moving psychedelics from research to therapy by developing patent drug discovery platforms, new drug delivery methods, novel formulation methodologies, and treatment regimens for mental health conditions.
